RPRX Stock Forecast: Royalty Pharma Plc Price Predictions for 2026-2027
The 9 Wall Street analysts covering Royalty Pharma Plc hold a median 12-month price target of $75 — +8.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 97 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Royalty Pharma Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (100): The shares have been drifting up relative to others.
Quality (71): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RPRX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RPRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +8.8% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2026 | TD Cowen | Maintains | Buy | $68 → $80 |
| 5 Nov 2026 | Citigroup | Maintains | Buy | $70 → $78 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Overweight | $65 → $67 |
| 8 Sept 2026 | TD Cowen | Maintains | Buy | $65 → $68 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $58 → $62 |
| 13 July 2026 | TD Cowen | Maintains | Buy | $50 → $65 |
| 7 May 2026 | Citigroup | Maintains | Buy | — |
| 7 May 2026 | JP Morgan | Maintains | Overweight | — |
| 21 Apr 2026 | UBS | Maintains | Buy | — |
| 10 Apr 2026 | Morgan Stanley | Maintains | Overweight | — |
| 30 Jan 2026 | UBS | Upgrade | Buy | — |
| 27 Jan 2026 | Citigroup | Maintains | Buy | — |
| 11 Dec 2025 | TD Cowen | Maintains | Buy | — |
| 10 Oct 2025 | Morgan Stanley | Maintains | Overweight | — |
| 30 Sept 2025 | Goldman Sachs | Initiates | Buy | — |
| 22 July 2025 | Citigroup | Maintains | Buy | — |
| 10 July 2025 | Morgan Stanley | Maintains | Overweight | — |
| 25 Oct 2024 | Citigroup | Maintains | Buy | — |
| 14 Aug 2024 | Goldman Sachs | Maintains | Buy | — |
| 11 July 2024 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RPRX.
This page is one stock. Monday covers all of them.
RPRX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RPRX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Royalty Pharma Plc returned +81.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RPRX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 44.7×
- Price / sales
- 15.0×
- Price / book
- 4.5×
- EV / EBITDA
- 24.5×
Cheaper than 18% of US stocks
Cheaper than 9% of US stocks
Cheaper than 21% of US stocks
Cheaper than 15% of US stocks
- Revenue growth (YoY)
- 13.3%
- Earnings growth (YoY)
- −49.1%
- Gross margin
- —
- Operating margin
- 64.4%
- Net margin
- —
Higher than 61% of US stocks
Higher than 11% of US stocks
Higher than 99% of US stocks
- Return on equity
- 12.1%
- Return on assets
- 5.4%
- Dividend yield
- 1.4%
Higher than 68% of US stocks
Higher than 78% of US stocks
Higher than 29% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Royalty Pharma Plc has a market value of $39.4B and an enterprise value of $41.5B.
Revenue in the twelve months to 30 June 2026: $2.5B. The latest quarter grew 16.5% year on year.
Net income over the same four quarters: $1.3B, a 53.2% net margin.
Diluted earnings per share, trailing twelve months: $1.46.
Free cash flow in the twelve months to 30 June 2026: $3.0B.
Royalty Pharma Plc spent $321.8M on share buybacks and $399.1M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 44.7×; forward P/E: 11.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.37%, paying out 60% of earnings.
Royalty Pharma Plc employs 100 people — $25.4M of revenue per employee.
Data provided by Twelve Data
RPRX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RPRX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Royalty Pharma Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RPRX
What is the RPRX stock price forecast for 2026-2027?
The 9 Wall Street analysts covering Royalty Pharma Plc have a median 12-month price target of $75, with estimates ranging from $67 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RPRX stock a buy right now?
Of the 9 analysts covering Royalty Pharma Plc, 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Royalty Pharma Plc 97 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RPRX?
As at 21 Nov 2026, Royalty Pharma Plc ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).
Will RPRX stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts implies +8.8% from the last close, and Ticker Nerd's factor model ranks Royalty Pharma Plc 97 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RPRX stock forecast for 2030?
No analyst covering Royalty Pharma Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $67 to $80 over the next 12 months.
How has RPRX stock performed over the past year?
Royalty Pharma Plc returned +81.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Royalty Pharma Plc do?
Royalty Pharma plc Class A Ordinary Shares represents an equity interest in Royalty Pharma plc, a New York-based biopharmaceutical royalty company. The company acquires and manages royalty interests tied to approved medicines and development-stage therapies, providing financing to drug developers and rights holders in exchange for a share of future product sales.
About Royalty Pharma Plc.
Royalty Pharma plc Class A Ordinary Shares represents an equity interest in Royalty Pharma plc, a New York-based biopharmaceutical royalty company. The company acquires and manages royalty interests tied to approved medicines and development-stage therapies, providing financing to drug developers and rights holders in exchange for a share of future product sales. Its portfolio spans treatments in areas such as rare diseases, oncology, neuroscience, immunology, hematology, respiratory disease, infectious disease, and diabetes. Royalty Pharma also supports innovation by partnering with biotechnology and pharmaceutical companies, academic institutions, and research organizations across the life sciences sector. Through this model, the company serves as a specialized capital provider in the healthcare market, linking long-term funding needs with recurring revenue streams from commercialized therapies and pipeline assets.
CEO Mr. Pablo Legorreta · 100 employees · United States · https://www.royaltypharma.com